Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1553-1559

  Zhao, Yue ^a   Hu, Jinyue ^b   Li, Rongguo ^a   Song, Jian ^a   Kang, Yujuan ^a   Liu, Si ^a   Zhang, Dongwei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Zhengzhou Third People's Hospital   (China)

Author keywords

Adoptive immunotherapy; Breast cancer; Natural killer cells; Transforming growth factor beta

Indexed keywords

EID: 84934300120     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S82616     Document Type: Article

References (26)

1. He DD, Wang CF, Cao LL, et al. Epidemic trend of female breast cancer incidence in Min Hang District, Shanghai. China Cancer. 2010;13:108-110.
2. Papamichail M, Perez SA, Gritzapis AD, Baxevanis C. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother. 2004;53:176-186.
3. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol. 2001;13:458-464.
4. Herberman RB. Cancer immunotherapy with natural killer cells. Semin Oncol. 2002;29:27-30.
5. Hallett WH, Murphy WJ. Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol. 2006;16:367-382.
6. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011;20:R93-R99.
7. Lee MY, Kim HJ, Kim MA, et al. Nek6 is involved in G2/M phase cell cycle arrest through DNA damage induced phosphorylation. Cell Cycle. 2008;7:2705-2709.
8. Wallace A, Kapoor V, Sun J, et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res. 2008;14:3966-3974.
9. Kelly RJ, Morris JC. Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol. 2010;7:15-26.
10. Ikushima H, Miyazono K. TGF-beta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415-424.
11. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64:7596-7603.
12. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172:7335-7340.
13. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5-23.
14. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
15. Polat MF, Taysi S, Polat S, et al. Elevated serum arginase activity levels in patients with breast cancer. Surg Today. 2003;33:655-661.
16. de Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther. 2009;9:1317-1332.
17. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009;69:8420-8428.
18. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol. 2009;2:166-176.
19. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res. 2007;13:5262-5270.
20. Crane CA, Han SJ, Barry JJ, et al. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 2010;12:7-13.
21. Tian M, Schiemann WP. The TGF-β paradox in human cancer: an update. Future Oncol. 2009;5:259-271.
22. Massague J, Gomis RR. The logic of TGF-β signaling. FEBS Lett. 2006;580:2811-2820.
23. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783-2810.
24. Runyan CE, Hayashida T, Hubchak S, Curley JF, Schnaper HW. Role of SARA (SMAD anchor for receptor activation) in maintenance of epithelial cell phenotype. J Biol Chem. 2009;284:2518-2519.
25. Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12:286-293.
26. Hussey GS, Chaudhury A, Dawson AE, et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 2011;41:419-431.